Galusic相关文献与解析，生知库 | 链接生命科学的每一步

Lucijanic, Marko; Krecak, Ivan; Soric, Ena; Sabljic, Anica; Galusic, Davor; Holik, Hrvoje; Perisa, Vlatka; Moric Peric, Martina; Zekanovic, Ivan; Budimir, Leonardo; Kusec, Rajko

血小板

发表日期：2025

文献求助收藏

Is There a Role for Daratumumab Retreatment in Patients with Relapsed/Refractory Multiple Myeloma?

达雷妥尤单抗再治疗在复发/难治性多发性骨髓瘤患者中是否发挥作用？

期刊:Biomedicines

影响因子:3.9

doi:10.3390/biomedicines13010207

Galusic, Davor; Krecak, Ivan; Blaslov, Viktor; Krstulovic Opara, Andela; Valkovic, Toni; Basic Kinda, Sandra

Gene Expression Analysis of Autophagy Markers in Primary and Secondary Myelofibrosis

原发性和继发性骨髓纤维化中自噬标志物的基因表达分析

期刊:Journal of Clinical Medicine

影响因子:3

doi:10.3390/jcm14072333.

Marin Medugorac ,Katarina Marija Glick ,Ana Livun ,Marko Lucijanic ,Davor Galusic ,Rajko Kusec

Evaluation of Absolute Neutrophil, Lymphocyte and Platelet Count and Their Ratios as Predictors of Thrombotic Risk in Patients with Prefibrotic and Overt Myelofibrosis

评估绝对中性粒细胞、淋巴细胞和血小板计数及其比值作为前纤维化和显性骨髓纤维化患者血栓风险预测指标的价值

期刊:Life-Basel

影响因子:3.4

doi:10.3390/life14040523

Lucijanic, Marko; Krecak, Ivan; Soric, Ena; Sabljic, Anica; Galusic, Davor; Holik, Hrvoje; Perisa, Vlatka; Moric Peric, Martina; Zekanovic, Ivan; Budimir, Josipa; Kusec, Rajko

Higher estimated plasma volume status is associated with increased thrombotic risk and impaired survival in patients with primary myelofibrosis

较高的血浆容量估计值与原发性骨髓纤维化患者的血栓风险增加和生存期缩短相关。

期刊:

影响因子:

doi:10.11613/BM.2023.020901

Lucijanic, Marko; Krecak, Ivan; Soric, Ena; Sabljic, Anica; Galusic, Davor; Holik, Hrvoje; Perisa, Vlatka; Peric, Martina Moric; Zekanovic, Ivan; Kusec, Rajko

心血管

发表日期：2023

文献求助收藏

Efficacy and Safety of Obinutuzumab-chemotherapy Combinations in Front-line Treatment of Follicular Non-Hodgkin Lymphoma During the COVID-19 Pandemic: A Study of KROHEM, the Croatian Cooperative Group for Hematologic Diseases

COVID-19 大流行期间，奥妥珠单抗联合化疗一线治疗滤泡性非霍奇金淋巴瘤的疗效和安全性：克罗地亚血液病合作组 KROHEM 的一项研究

期刊:Hemasphere

影响因子:14.6

doi:10.1097/HS9.0000000000000807

Galusic, Davor; Basic-Kinda, Sandra; Pijuk, Andela; Milunovic, Vibor; Dreta, Barbara; Franjic, Neven; Coha, Bozena; Sincic-Petricevic, Jasminka; Gacina, Petar; Pejsa, Vlatko; Lucijanic, Marko; Aurer, Igor

淋巴瘤

发表日期：2022

文献求助收藏

Identification and Immunological Characterization of the Ligand Domain of Plasmodium vivax Reticulocyte Binding Protein 1a

间日疟原虫网织红细胞结合蛋白1a配体结构域的鉴定和免疫学表征

期刊:Journal of Infectious Diseases

影响因子:4.5

doi:10.1093/infdis/jiy273

Ntumngia, Francis B; Thomson-Luque, Richard; Galusic, Sandra; Frato, Gabriel; Frischmann, Sarah; Peabody, David S; Chackerian, Bryce; Ferreira, Marcelo U; King, Christopher L; Adams, John H

Extreme Thrombocytosis in Patients with Overt Myelofibrosis and Its Clinical Associations

骨髓纤维化患者的极度血小板增多症及其临床关联

Is There a Role for Daratumumab Retreatment in Patients with Relapsed/Refractory Multiple Myeloma?

达雷妥尤单抗再治疗在复发/难治性多发性骨髓瘤患者中是否发挥作用？

Gene Expression Analysis of Autophagy Markers in Primary and Secondary Myelofibrosis

原发性和继发性骨髓纤维化中自噬标志物的基因表达分析

Evaluation of Absolute Neutrophil, Lymphocyte and Platelet Count and Their Ratios as Predictors of Thrombotic Risk in Patients with Prefibrotic and Overt Myelofibrosis

评估绝对中性粒细胞、淋巴细胞和血小板计数及其比值作为前纤维化和显性骨髓纤维化患者血栓风险预测指标的价值

Higher estimated plasma volume status is associated with increased thrombotic risk and impaired survival in patients with primary myelofibrosis

较高的血浆容量估计值与原发性骨髓纤维化患者的血栓风险增加和生存期缩短相关。

Efficacy and Safety of Obinutuzumab-chemotherapy Combinations in Front-line Treatment of Follicular Non-Hodgkin Lymphoma During the COVID-19 Pandemic: A Study of KROHEM, the Croatian Cooperative Group for Hematologic Diseases

COVID-19 大流行期间，奥妥珠单抗联合化疗一线治疗滤泡性非霍奇金淋巴瘤的疗效和安全性：克罗地亚血液病合作组 KROHEM 的一项研究

Identification and Immunological Characterization of the Ligand Domain of Plasmodium vivax Reticulocyte Binding Protein 1a

间日疟原虫网织红细胞结合蛋白1a配体结构域的鉴定和免疫学表征